Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience
Author:
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference20 articles.
1. Reliability of human epidermal growth factor receptor 2 immunohistochemistry in breast core needle biopsies;A Lebeau;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2010
2. Current technologies for HER2 testing in breast cancer;CB Moelans;Critical reviews in oncology/hematology,2011
3. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer;AC Wolff;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2007
4. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update;AC Wolff;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2013
5. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization;A Lebeau;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2001
Cited by 53 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. ERBB2‐amplified lobular breast carcinoma exhibits concomitant CDK12 co‐amplification associated with poor prognostic features;The Journal of Pathology: Clinical Research;2024-01-21
2. Prognostic factors in inflammatory breast cancer: A single-center study;Breast Disease;2023-01-05
3. Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy;Scientific Reports;2022-01-07
4. Elucidation of HER2/neu and Wilms’ tumor 1 immunohistochemical expression in endometrial carcinomas regarding the diagnostic and prognostic significance;Egyptian Journal of Pathology;2022
5. Combining Neratinib with CDK4/6, mTOR, and MEK Inhibitors in Models of HER2-positive Cancer;Clinical Cancer Research;2021-01-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3